Scleral contact lenses in normal corneas: is it possible to improve visual performance?
Revista Brasileira de Oftalmologia · 08.04.2026 · 85
DOI: 10.37039/1982.8551.20260025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Brasileira de Oftalmologia, erschienen am 08.04.2026. Verfasst von Cristina Cagliari und 1 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Objective
To analyze visual performance in digitally active volunteers using ScCLs.
Methods
ScCLs were fit in seven participants and evaluated during four visits over 45 consecutive days. Reading speed tests were performed with MNREAD-P charts and texts developed by the Department of Speech Therapy of the authors’ institution. Post-study, participants were interviewed and completed the 8-item Contact Lens Dry Eye Questionnaire (CLDEQ-8).
Results
During ScCL wear, 85.7% showed increased reading speed on MNREAD-P charts, with similar results on the texts of the authors’ institution. Interviews highlighted initial ScCL handling difficulty, improved comfort, and preference over soft lenses for physical activities.
Conclusion
This study underscores the need to explore new contexts impacting digital tasks requiring optimal visual performance, suggesting ScCLs as beneficial. Further research is necessary to elucidate these aspects.
Zitieren
APA
Cagliari, C., & Schor, P. (2026). Scleral contact lenses in normal corneas: is it possible to improve visual performance?. Revista Brasileira de Oftalmologia, 85. https://doi.org/10.37039/1982.8551.20260025
Vancouver
Cagliari C, Schor P. Scleral contact lenses in normal corneas: is it possible to improve visual performance?. Revista Brasileira de Oftalmologia. 2026;85. doi:10.37039/1982.8551.20260025
BibTeX
@article{Cagliari2026,
author = {Cagliari, Cristina and Schor, Paulo},
title = {Scleral contact lenses in normal corneas: is it possible to improve visual performance?},
journal = {Revista Brasileira de Oftalmologia},
year = {2026},
volume = {85},
doi = {10.37039/1982.8551.20260025}
}
EUVIMED